Department of Psychiatry, Radboud University Medical Center, Reinier Postlaan 10, 6525 GC Nijmegen, The Netherlands.
Institute of Psychology, Leiden University, Wassenaarseweg 52, 2333 AK Leiden, The Netherlands; Department of Psychiatry, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
J Affect Disord. 2015 Nov 15;187:54-61. doi: 10.1016/j.jad.2015.08.023. Epub 2015 Aug 18.
Mindfulness-based cognitive therapy (MBCT) and maintenance antidepressant medication (mADM) both reduce the risk of relapse in recurrent depression, but their combination has not been studied. Our aim was to investigate whether the addition of MBCT to mADM is a more effective prevention strategy than mADM alone.
This study is one of two multicenter randomised trials comparing the combination of MBCT and mADM to either intervention on its own. In the current trial, recurrently depressed patients in remission who had been using mADM for 6 months or longer (n=68), were randomly allocated to either MBCT+mADM (n=33) or mADM alone (n=35). Primary outcome was depressive relapse/recurrence within 15 months. Key secondary outcomes were time to relapse/recurrence and depression severity. Analyses were based on intention-to-treat.
There were no significant differences between the groups on any of the outcome measures.
The current study included patients who had recovered from depression with mADM and who preferred the certainty of continuing medication to the possibility of participating in MBCT. Lower expectations of mindfulness in the current trial, compared with the parallel trial, may have caused selection bias. In addition, recruitment was hampered by the increasing availability of MBCT in the Netherlands, and even about a quarter of participants included in the trial who were allocated to the control group chose to get MBCT elsewhere.
For this selection of recurrently depressed patients in remission and using mADM for 6 months or longer, MBCT did not further reduce their risk for relapse/recurrence or their (residual) depressive symptoms.
正念认知疗法(MBCT)和维持性抗抑郁药物(mADM)均可降低复发性抑郁症的复发风险,但尚未研究两者的联合应用。我们的目的是研究 MBCT 联合 mADM 是否比单独使用 mADM 更能有效预防复发。
这是两项多中心随机试验之一,旨在比较 MBCT 联合 mADM 与单独干预的效果。在当前试验中,缓解期且使用 mADM 治疗 6 个月或更长时间的复发性抑郁症患者(n=68)被随机分为 MBCT+mADM 组(n=33)或 mADM 组(n=35)。主要结局为 15 个月内的抑郁复发/再发。次要结局包括复发/再发时间和抑郁严重程度。分析基于意向治疗。
两组在任何结局指标上均无显著差异。
当前研究纳入了正在使用 mADM 治疗且已从抑郁症中康复的患者,他们更倾向于继续使用药物,而不愿参加 MBCT。与平行试验相比,当前试验中对正念的期望较低,可能导致选择偏倚。此外,由于荷兰 MBCT 的可及性增加,招募受到阻碍,即使是被分配到对照组的 1/4 左右的参与者也选择在其他地方接受 MBCT。
对于选择缓解期且正在使用 mADM 治疗 6 个月或更长时间的复发性抑郁症患者,MBCT 并未进一步降低其复发/再发风险或(残留)抑郁症状。